Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2022-08-31 Regulatory Filings
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1458 characters), and it primarily serves as a regulatory filing to inform the SEC and investors about a press release event. According to the rules, Form 6-K filings are considered Regulatory Filings (RNS) as they are miscellaneous filings that do not fit into other specific categories and often include announcements or updates without full financial reports.
2022-08-31 English
Regulatory Filings 2022
Regulatory Filings Classification · 90% confidence The provided document text appears to be heavily encoded or corrupted, containing mostly non-readable characters and no discernible content related to any specific financial filing type. There are no clear references to regulatory bodies, report titles, fiscal periods, or keywords that would indicate the nature of the document. Given the lack of meaningful content and the inability to identify any specific filing type, the document should be classified under the fallback category for miscellaneous or unclear filings, which is Regulatory Filings (RNS). The document length is sufficient to be a full report, but the content is not interpretable, so it cannot be classified as a substantive report type.
2022-08-24 English
SC 13D/A
Major Shareholding Notification
2022-08-24 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group PLC, pursuant to SEC rules. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1456 characters), and it primarily serves as a regulatory filing to report a press release. According to the rules, Form 6-K filings are considered Regulatory Filings (RNS) as they are miscellaneous filings that do not fit into other specific categories and often include updates or announcements without full financial reports.
2022-08-22 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a correspondence letter from Mereo BioPharma Group plc to the SEC responding to comments on their previously filed Form 20-F Annual Report for the fiscal year ended December 31, 2021. The letter discusses accounting policies applied in the Annual Report, specifically related to intangible assets and revenue recognition under IFRS standards. It references the Form 20-F filing and clarifies accounting treatments but does not itself contain financial statements or substantive financial data. The document is a regulatory correspondence related to the Annual Report, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as it is a response to SEC staff comments and not the Annual Report or Audit Report itself.
2022-08-19 English
Regulatory Filings 2022
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement. Given the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The confidence is moderate due to the inability to extract meaningful content from the text.
2022-08-08 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.